WATCH OUR EPIC STORY VIDEO
Epic Sciences is proud to be partnering with The San Marcos Promise, a nonprofit foundation working to connect education, business, and community leaders to impact student futures. SMP’s programs target students in the San Marcos Unified School District (SMUSD), where 69% of the 21,000 K-12 students are students of color, and 41.7% of students qualify for the free or reduced meal program.
SMP’s goal is to help SMUSD students discover their interests and strengths and take the necessary steps to prepare for a successful career. With a STEM-focus, SMP’s programs have the potential to increase college enrollment rates among all students and increase entry-level wages for students directly joining the workforce. Epic Sciences’ volunteers will partner with SMP to provide mentoring, career advice, and coaching to students.
We’re looking for inspired visionaries – diverse individuals with a passion for precision and a deep commitment to making a profound difference. Join us to transform cancer care and extend lives, cell by cell, person by person.
BOARD OF DIRECTORS
Gregory T. Lucier is a 30+ year veteran of the healthcare industry. He currently heads Corza Health, Inc., a mergers and acquisition healthcare company focused on life science and medical technology. Mr. Lucier most recently served as Chairman and CEO of NuVasive, a global technology leader in minimally invasive spine and orthopedic surgery that grew revenue from approximately $775 million to more than $1 billion in just over three years as CEO.
Lucier serves on several public and private company boards, including Catalent, Dentsply Sirona, Berkley Lights, Maravai LifeSciences, and Epic Sciences. He previously served as a director of Life Technologies, CareFusion until its sale to Becton Dickinson, Invuity until its sale to Stryker, and of NuVasive.
From 2003-2014, he was Chairman and CEO of Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific for $15.4 billion. During his 11-year tenure, he led the company from a small start-up known as Invitrogen in 2003 and directed the acquisition and merger of Invitrogen with Applied Biosystems in 2008 into the renamed Life Technologies. By 2008, he had transformed the organization into a global, world-leading biotechnology firm with 50,000 products, 10,000 employees and nearly $4 billion in sales in more than 180 countries.
Mr. Lucier was responsible for fostering a culture of excellence at Life Technologies, and applied his many years of strategic management experience to help champion an era of personalized medicine. His early career included roles as a corporate officer of General Electric Company and as an executive at GE Medical Systems.
Gregory C. Critchfield, MD
Dr. Critchfield is chairman, president and CEO of Sera Prognostics, Inc. and the former president of Myriad Genetic Laboratories, Inc. He led its transformation into one of the world’s leading molecular diagnostics companies. Under his direction, Myriad Genetic Laboratories launched seven novel molecular diagnostic products across a variety of technology platforms, posting 52 percent compounded annual revenue growth from 1998 through 2010. Prior to joining Myriad, Dr. Critchfield was Chief Medical & Science Officer at Quest Diagnostics, Inc., overseeing medical affairs and innovation activities during its transition from Corning Clinical Laboratories.
He has also served on the faculty of three medical schools — University of Minnesota, Wayne State University, and Duke University — and was a practicing clinical pathologist with Intermountain Healthcare.
Andrew ElBardissi, MD
Dr. Andrew ElBardissi is an investor on the Private Transaction team at Deerfield Management. Prior to joining Deerfield, Dr. ElBardissi held roles as an early stage life-sciences investor and as an Investment Banker at J.P. Morgan’s Healthcare practice. Dr. ElBardissi holds an MD from the Mayo Clinic, an MPH in Quantitative Methods from Harvard University, an MBA from Harvard Business School. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ), has over 30 publications in leading peer-reviewed scientific journals, and has presented his research at numerous medical and surgical conferences.
Dr. ElBardissi’s board memberships include Acutus, Farapulse, SentreHeart, Sollis Therapeutics, vWave, Conventus, Neochord, and Incarda Therapeutics.
John Zhao, CFA
Mr. John Zhao has 20 years of experience in financial, portfolio management, and risk control with extensive resources in the financial industry.
Mr. Zhao Joined Hermed Capital in 2015, Mr. Zhao led the financial and risk control team, in charge of financial and legal due diligence of all deals, involved in the negotiation, execution, portfolio management, and exit. Prior to joining Hermed Capital, Mr. Zhao has been working in MNCs for years, e.g. the investment director of SK (China), senior manager of PPF (China) Investment and credit rating analyst in DaGong Global Credit Rating Co., Ltd.
Mr. Zhao completed an MBA degree in finance from Shanghai University of Finance and Economics; CFA Charter holder in 2006.
Kim Kamdar, PhD
Kim Kamdar joined Domain Associates in 2005 and became a partner in 2011. With a background in small molecule drug discovery, Dr. Kamdar has been involved in cutting-edge therapeutic start-ups, using her expertise to identify companies with promising molecular and companion diagnostics that support personalized medicine.
Her present board memberships include Ariosa Diagnostics, Epic Sciences, Lithera, Obalon Therapeutics, ROX Medical, Sera Prognostics, Sonexa Therapeutics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. She was also involved with Corthera until its sale to Novartis in February 2010 and BiPar Sciences until its acquisition by Sanofi-Aventis in April 2009.
Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capital and a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology.
Dr. Kamdar has authored ten papers and received seven patents. She completed her BA at Northwestern University and her PhD in biochemistry and genetics at Emory University. Dr. Kamdar serves as an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine and the Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. She is also a board member of San Diego’s CONNECT Foundation and the Hastings Center.
Charles Kennedy, MD
Blue Ox Healthcare Partners
Dr. Charles Kennedy has a proven track record as a visionary healthcare leader and has been recognized as an expert in health information technology. Currently, Dr. Kennedy is managing partner at Blue Ox Healthcare Partners, leading their efforts to identify companies with innovations in healthcare services, technology, and devices which can enable providers and health plans to optimize value-based health care strategies.
Prior to joining Blue Ox, Dr. Kennedy held multiple executive positions with Aetna, including Vice President and Chief Medical Officer for Clinical Integration and Chief Population Officer, where he led and implemented population health management programs. Additionally, Dr. Kennedy has served in several executive leadership positions with WellPoint Inc., CareAssured.com, and Blue Shield of California.
Dr. Kennedy’s vast experience and leadership have earned him multiple board appointments and he currently serves as a Ventures Advisory Group Board member with Rethink Health and as an Insurance Industry representative with Health Information Technology Policy Committee.
Dr. Kennedy completed his Bachelor of Science in Genetics at the University of California at Berkeley. He holds an MD in Internal Medicine from the University of California at Los Angeles and his MBA in Corporate Strategy and Health Care Economics from Stanford University.
Murali Prahalad, PhD
Murali Prahalad, PhD has two decades of experience in the technology and life science industries. He most recently served as president and CEO of Epic Sciences for 6 years. Under his leadership, Epic commercially launched the first predictive diagnostic test of therapy response in metastatic prostate cancer that has also been reimbursed by Medicare. During the same period Epic significantly expanded partnerships with biopharma companies, its proprietary Functional Cell Profiling technology platform was fully automated for high-volume testing and over $128MM of venture financing was raised to clinically advance a portfolio of practice changing tests in prostate cancer, breast cancer and immuno-oncology. Prior to joining Epic, Dr. Prahalad served as Vice President of Corporate Strategy at Life Technologies, where he helped shape the organic and inorganic investment priorities across the company’s research tools, clinical diagnostic and applied market portfolios. Before Life Technologies, Dr. Prahalad was Vice President of Business Development at Sequenom, Inc.
Dr. Prahalad received a PhD in biochemistry and molecular pharmacology as well as an MS in medical sciences from Harvard University. He also possesses a BS (Hons) in cellular & molecular biology and economics from the University of Michigan.
Lloyd Sanders joined Epic Sciences as President and Chief Executive Officer in 2019 with more than 20 years of diagnostics and pharmaceutical industry experience, most of it focused on oncology. Prior to joining Epic, he served as president of the oncology segment of Myriad Genetics, overseeing the oncology, urology and dermatology commercial organizations. While at Myriad, he was responsible for the sales, marketing, medical, customer service and laboratory operations for numerous market-leading commercial products, including molecular diagnostics for risk assessment, diagnosis/screening, prognosis and selection of therapies for breast, prostate, colorectal and other cancers.
Previously, Mr. Sanders served as chief operating officer at Dey Pharma, a division of Mylan, overseeing sales, marketing and medical affairs, including the EpiPen® flagship brand. Prior to Dey Pharma, he held several leadership positions including responsibility for the commercial growth of a number of oncology products at Sanofi-Synthelabo, subsequently Sanofi-Aventis, where he led the successful restructuring and integration of two companies’ sales forces after the merger. Mr. Sanders started his pharmaceutical career and participated in oncology product launches at Pharmacia (now Pfizer).
Mr. Sanders earned a Bachelor’s business degree with an emphasis in marketing from Memphis State University.